Understanding CML: Your Journey from Diagnosis to Treatment

Opinion
Video

A panel of experts on introduce a discussion on chronic myeloid leukemia (CML) with an overview of the disease, focusing on its subtypes and characteristics.

This program was made possible with support from Novartis Pharmaceuticals.

Video content above is prompted by the following questions:

  • Please provide some background on CML. What are the different subtypes of CML and how do they differ in terms of presentation and management?
  • Can you explain the typical prognosis and disease course for someone diagnosed with CML? How do you educate newly diagnosed patients on what to expect?
Recent Videos
Determining the molecular characteristics of one’s disease may influence the therapy employed in the first line as well as subsequent settings.
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
A 2-way communication between providers and patients may help facilitate dose modifications to help better manage adverse effects.
Treatment with AML depends on a variety of factors, including stage of treatment, transplant eligibility, and mutational status.
Related Content
A 13-week Good Laboratory Practice toxicity study demonstrated that UB-VV111 was well-tolerated in CD34-humanized mice.

FDA Grants Fast Track Designation to UB-VV111 in Select B-Cell Malignancies

Tim Cortese
October 1st 2025
Article

A phase 1 trial is evaluating UB-VV111 with and without rapamycin as treatment for patients with CLL and LBCL who received at least 2 prior therapies.

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Elizabeth Shpall, MD
May 29th 2019
Podcast

Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.

Data from KOMET-001 support ziftomenib as a new potential option for patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.

Ziftomenib Shows Significant Benefit in Relapsed/Refractory NPM1+ AML

Russ Conroy
September 26th 2025
Article

Data from KOMET-001 support ziftomenib as a new potential option for patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.

Immunotherapy Approaches in AML

Immunotherapy Approaches in AML

Naval Daver, MD
January 17th 2019
Podcast

Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.

The overall safety profile of pirtobrutinib was consistent with previously reported trials across various CLL and SLL settings.

Pirtobrutinib Improves PFS in Treatment-Naïve CLL/SLL Without 17p Deletions

Tim Cortese
September 8th 2025
Article

Results from the phase 3 BRUIN CLL-313 trial show that OS trended favorably for pirtobrutinib vs chemoimmunotherapy in this CLL and SLL population.

Chronic myeloid leukemia was once known as a deadly disease, renowned for its difficulty to treat.

Recapping A Quarter Decade of Chronic Myeloid Leukemia Therapy

Tim Cortese
September 2nd 2025
Article

Jorge Cortes, MD, believes that, despite the rapid improvements made in CML treatment, there is always more to be done to help patients.